Global Cell Lysis and Disruption Market valued at USD 5.21 billion in 2023, projected to reach USD 10.92 billion by 2032 with a CAGR of 8.61%. Growth driven by biopharmaceutical industry expansion, demand for recombinant proteins, and cell-based research studies. Cell lysis crucial for drug discovery, diagnostics, and vaccine development.

Reagent-based techniques dominated the market in 2023, capturing 76.25% revenue share. Reagents and consumables led with a 65.41% market share. Mammalian cells accounted for 46.30% market share in 2023, while yeast, algae, and fungi segment expected to grow rapidly. North America holds 38.10% market share, with Asia Pacific projected to be the fastest-growing region.

Recent developments include next-gen automated lysis platform launch by Thermo Fisher Scientific, microfluidics-based cell disruption device by Danaher Corporation, and expanded consumables portfolio by Merck KGaA. Market trends show increasing investments in bioprocessing technology, automated systems reducing sample preparation time, and growing demand for single-use bioprocessing solutions in lysis workflows.

SNS Insider provides critical insights on cell lysis technologies adoption, competitive landscape, and future opportunities. Report covers disease incidence, research adoption metrics, healthcare spending benchmarks, regulatory insights, technological advancements, and competitive analysis. Market scope includes segments by technique, product, cell type, application, end-use, and regional analysis.

For more information and to access the full report on the Cell Lysis and Disruption Market, visit the SNS Insider website.

Read more at GlobeNewswire: Cell Lysis and Disruption Market to Surpass USD 10.9